21 CFR 211.160
General requirements.
- Inspections citing it: 2,969
- Of those classified, ended OAI: 27%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 211.160(b)
- 1,449 · Scientifically sound laboratory controls
- 211.160(a)
- 665 · Following/documenting laboratory controls
- 211.160(b)(4)
- 538 · Calibration - at intervals, written program, remedial action
- 211.160(b)(3)
- 158 · Acceptance of drug products
- 211.160(b)(1)
- 96 · Incoming lots - conformance to written specs-
- 211.160(b)(2)
- 63 · In-process samples representative, identified properly
Regulation Text
eCFR, as of Nov 6, 2026(a) The establishment of any specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms required by this subpart, including any change in such specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms, shall be drafted by the appropriate organizational unit and reviewed and approved by the quality control unit. The requirements in this subpart shall be followed and shall be documented at the time of performance. Any deviation from the written specifications, standards, sampling plans, test procedures, or other laboratory control mechanisms shall be recorded and justified.
(b) Laboratory controls shall include the establishment of scientifically sound and appropriate specifications, standards, sampling plans, and test procedures designed to assure that components, drug product containers, closures, in-process materials, labeling, and drug products conform to appropriate standards of identity, strength, quality, and purity. Laboratory controls shall include:
(1) Determination of conformity to applicable written specifications for the acceptance of each lot within each shipment of components, drug product containers, closures, and labeling used in the manufacture, processing, packing, or holding of drug products. The specifications shall include a description of the sampling and testing procedures used. Samples shall be representative and adequately identified. Such procedures shall also require appropriate retesting of any component, drug product container, or closure that is subject to deterioration.
(2) Determination of conformance to written specifications and a description of sampling and testing procedures for in-process materials. Such samples shall be representative and properly identified.
(3) Determination of conformance to written descriptions of sampling procedures and appropriate specifications for drug products. Such samples shall be representative and properly identified.
(4) The calibration of instruments, apparatus, gauges, and recording devices at suitable intervals in accordance with an established written program containing specific directions, schedules, limits for accuracy and precision, and provisions for remedial action in the event accuracy and/or precision limits are not met. Instruments, apparatus, gauges, and recording devices not meeting established specifications shall not be used.
Recently Cited Sites
Newest inspections citing this section; each opens the site- ACTA Laboratories, Inc.United States · Sep 4, 2026
- AptaPharma Inc.United States · Aug 14, 2026
- Steril-Gene Life Sciences Private LtdIndia · Aug 12, 2026
- Fuller Industries IncUnited States · Jul 23, 2026
- Biochemical and Scientific Consultants ccSouth Africa · Jul 20, 2026
- Canyon Rush, LLCUnited States · May 15, 2026
- Sombra Cosmetics, IncUnited States · May 8, 2026
- Samson Pharmaceuticals, IncUnited States · Apr 29, 2026
- Similasan AGSwitzerland · Apr 27, 2026
- Hanlim Pharm Co. Ltd.Unknown · Apr 24, 2026
- Westwood Laboratories, LLC.United States · Mar 26, 2026
- The Mentholatum CompanyUnited States · Mar 23, 2026
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR